Clinical Research Directory

Inclusion Criteria: * Subjects who are voluntarily able to give informed consent * Subjects who can participate in all aspects of this clinical study * Males and females aged from ≥ 18 to ≤ 80 years, at screening visit * Diagnosis of moderate to severe UC established by clinical and endoscopic evidence. * Biological therapy naïve patients. Exclusion Criteria: * \- Previous exposure to IFX or UST or any other in IFX or UST-containing product * Has a history of hypersensitivity or allergies to the ingredients of IFX or UST formulations * Unstable angina * Moderate or severe heart failure (defined as New York Heart Association Class III or IV) * Chronic respiratory failure * History of any major neurological disorders including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease * Chronic hepatitis B or C infection. Patients with positive viral serology at screening for infection with hepatitis B (HBV) or hepatitis C virus (HCV) may be eligible if the polymerase chain reaction test is negative, and the patients receive standard of-care antiviral prophylaxis (if applicable) * Known severe chronic kidney failure * Known severe chronic liver failure * Known active or latent tuberculosis * Ongoing HIV infection